Jade Biosciences Strengthens Leadership With Appointment Of Brad Dahms As Chief Financial Officer

Jade Biosciences, Inc., a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, has announced the appointment of Brad Dahms as its new Chief Financial Officer. With a strong background in finance and strategic leadership within the life sciences sector, Mr. Dahms brings valuable experience to support Jade Biosciences’ continued growth and development.

Mr. Dahms most recently served as Chief Financial Officer and Chief Business Officer at IDRx, a clinical-stage oncology company. During his time there, he was responsible for overseeing financial operations, business development, and investor relations. He played a key role in preparing the company for public markets and guided its acquisition by GSK in a deal valued at up to $1.15 billion.

Before IDRx, Mr. Dahms was the Chief Financial Officer at Theseus Pharmaceuticals, where he successfully led the company through its initial public offering and its eventual sale to Concentra Biosciences. Earlier in his career, he held the CFO position at Selecta Biosciences, where he was instrumental in securing multiple rounds of financing and managing strategic partnerships critical to the company’s advancement.

Tom Frohlich, Chief Executive Officer of Jade Biosciences, stated, “Brad is a proven strategic and financial leader with a strong track record guiding biotech companies through multiple phases of growth. His expertise across corporate strategy, business development, and capital markets makes him a valuable addition as we build on the momentum of our recent Nasdaq listing and private financing, advance our lead candidate JADE101 into the clinic this year for IgA nephropathy, and continue progressing a pipeline of potentially best-in-class therapies for autoimmune diseases.”

Mr. Dahms stated, “I’m honored to join the talented team at Jade and contribute to the company’s next phase of growth. With a clear strategy and a pipeline aimed at meaningful innovation in treating autoimmune diseases, we are well-positioned to execute and deliver value.”

Throughout his career, Mr. Dahms has overseen a wide range of core business functions including finance, corporate development, information technology, and both investor and public relations. His professional journey began in healthcare investment banking, with roles at leading firms such as J.P. Morgan, RBC Capital Markets, and Cantor Fitzgerald.

Mr. Dahms holds a Bachelor of Science degree in Economics, with honors, from The Ohio State University. With this appointment, Jade Biosciences strengthens its executive leadership team, bringing in seasoned financial expertise to support its mission of advancing innovative treatments for autoimmune diseases and building long-term value for stakeholders.